We recently identified activation of phosphatidylinositol 3 0 -kinase (PI3K)/Akt as a novel predictor of poor outcome in neuroblastoma. Here, we investigated the effect of smallmolecule PI3K inhibitors on chemosensitivity. We provide first evidence that PI3K inhibitors, for example PI103, synergize with various chemotherapeutics (Doxorubicin, Etoposide, Topotecan, Cisplatin, Vincristine and Taxol) to trigger apoptosis in neuroblastoma cells (combination index: high synergy). Mechanistic studies reveal that PI103 cooperates with Doxorubicin to reduce Mcl-1 expression and Bim EL phosphorylation and to upregulate Noxa and Bim EL levels. This shifted ratio of pro-and antiapoptotic Bcl-2 proteins results in increased Bax/Bak conformational change, loss of mitochondrial membrane potential, cytochrome c release, caspase activation and caspase-dependent apoptosis. Although Mcl-1 knockdown enhances Doxorubicin-and PI103-induced apoptosis, silencing of Noxa, Bax/ Bak or p53 reduces apoptosis, underscoring the functional relevance of the Doxorubicin-and PI103-mediated modulation of these proteins for chemosensitization. Bcl-2 overexpression inhibits Bax activation, mitochondrial perturbations, cleavage of caspases and Bid, and apoptosis, confirming the central role of the mitochondrial pathway for chemosensitization. Interestingly, the broad-range caspase inhibitor zVAD.fmk does not interfere with Bax activation or mitochondrial outer membrane permeabilization, whereas it blocks caspase activation and apoptosis, thus placing mitochondrial events upstream of caspase activation. Importantly, PI103 and Doxorubicin cooperate to induce apoptosis and to suppress tumor growth in patients' derived primary neuroblastoma cells and in an in vivo neuroblastoma model, underlining the clinical relevance of the results. Thus, targeting PI3K presents a novel and promising strategy to sensitize neuroblastoma cells for chemotherapy-induced apoptosis, which has important implications for the development of targeted therapies for neuroblastoma.
Intact apoptosis pathways are critical for chemotherapyinduced cytotoxicity and are initiated through the death receptor (extrinsic) pathway or the mitochondrial (intrinsic) pathway, resulting in activation of caspases (Fulda and Debatin, 2006) . Mitochondrial outer membrane permeabilization is tightly controlled by the Bcl-2 family of proteins, for example, antiapoptotic members such as Bcl-2, Bcl-X L and Mcl-1 and pro-apoptotic molecules such as Bax, Bak and BH3 domain only molecules (Adams and Cory, 2007) .
The phosphatidylinositol 3 0 -kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway is a key regulator of pro-survival signals (Engelman, 2009 ). Once activated, Akt controls various biological responses including inhibition of apoptosis, which is mediated by direct phosphorylation of apoptosis signaling molecules or indirectly by modulating the activity of transcription factors (Shaw and Cantley, 2006) . Aberrant activation of the PI3K/Akt/mTOR survival cascade is a characteristic feature of many human malignancies and has been associated with treatment resistance and poor prognosis (Engelman, 2009) . In neuroblastoma, the most frequent pediatric solid tumor outside the central nervous system (Maris et al., 2007) , PI3K/Akt pathway activation can be caused, for example, by increased expression of tyrosine kinase receptor B (Jaboin et al., 2002) or by amplification or mutation of anaplastic lymphoma kinase (Chen et al., 2008) . Recently, we identified activation of the PI3K/Akt pathway as a new predictor of poor outcome, indicating that this pathway presents a clinically relevant therapeutic target in neuroblastoma (Opel et al., 2007; Fulda, 2009) . We therefore investigated in the present study whether targeting aberrant PI3K signaling by small-molecule inhibitors can be exploited as a novel strategy to increase chemosensitivity of neuroblastoma.
Initially, we determined the optimal conditions under which the recently developed dual class I PI3K/mTOR inhibitor PI103 (Liu et al., 2009 ) blocks PI3K-mediated signaling. Dose response and kinetic analysis revealed that PI103 inhibits PI3K signaling at nanomolar concentrations rapidly and for a prolonged time period of up to 48 h (Supplementary Figure 1a) . The broadrange PI3K inhibitor LY294002 was used as a positive control (Supplementary Figure 1a) .
Next, we asked whether a subtoxic concentration of PI103 that causes little apoptosis (Supplementary Figure 1b) may modulate the chemosensitivity of neuroblastoma cells. Importantly, PI103 enhanced Doxorubicin-induced apoptosis in a highly synergistical manner in several neuroblastoma cell lines (Figure 1a , combination indexo0.1 (Supplementary Figure 1c) ). A similar sensitization for apoptosis by PI3K inhibitors was found for various chemotherapeutic drugs from different pharmacological classes that are commonly used for treating neuroblastoma patients, including Etoposide, Topotecan, Cisplatin, Vincristine and Taxol (Supplementary Figure 1d) and was also confirmed by Annexin-V staining (Supplementary Figure 1e) . Thus, PI3K inhibitors prime neuroblastoma cells for chemotherapy-induced apoptosis.
To gain insight into the molecular mechanisms responsible for apoptosis sensitization by PI3K inhibition, we used Doxorubicin, as it potently acted in concert with PI3K inhibitors (Figure 1a ). PI103 or LY294002 enhanced Doxorubicin-induced cleavage of caspase-8, -9 and -3, processing of Bid into active tBid, translocation of tBid to mitochondria, loss of mitochondrial membrane potential and cytochrome c release into the cytosol (Supplementary Figure 2) . The broad-range caspase inhibitor zVAD.fmk almost completely blocked apoptosis upon combined treatment with chemotherapeutics and PI103 ( Supplementary  Figure 2b) , demonstrating caspase dependency.
Monitoring of key apoptosis regulators revealed that combined treatment with Doxorubicin and PI103 or LY294002 caused decreased expression of Mcl-1, reduced phosphorylation of Bim EL as evident by a downward mobility shift of Bim EL , and increased levels of Noxa and BimEL, as well as decreased expression of XIAP (Figure 1b Supplementary Figure 4) , pointing to transcriptionindependent mechanisms of Bax and Bak activation, for example by cytoplasmic p53 (Chipuk et al., 2004; Leu et al., 2004) . Simultaneous knockdown of Bax and Bak significantly reduced Doxorubicin-and PI103-mediated apoptosis (Figure 1d ), demonstrating that Bax and Bak are required for PI103-mediated sensitization to Doxorubicin-induced apoptosis.
To explore the functional relevance of potential upstream regulators of Bax/Bak-dependent mitochondrial apoptosis, we silenced Mcl-1, Noxa and p53 by RNA interference, as they were substantially altered upon treatment with Doxorubicin and PI3K inhibitors (Figure 1b) . Knockdown of Noxa significantly reduced apoptosis, whereas silencing of Mcl-1 increased apoptosis following treatment with Doxorubicin or Doxorubicin combined with PI103 (Figure 2a) . Also, knockdown of p53 markedly inhibited apoptosis following treatment with Doxorubicin and PI103 or LY294002 (Figure 2b) . Interestingly, activation of Bax, upregulation of Puma, loss of mitochondrial membrane potential and activation of caspase-8, -9 and -3 upon combined treatment with Doxorubicin and PI103 or LY294002 were all substantially suppressed in p53 knockdown cells (Figures 2c and d) . By comparison, Noxa was similarly upregulated by Doxorubicin and PI3K inhibitors irrespective of p53 (Figure 2d ), pointing to p53-independent upregulation of Noxa. There is precedence of increased Noxa expression in response to DNA damage independently of p53 (Fei et al., 2002; Flinterman et al., 2005) , which has been linked to the p53 relative p73 (Flinterman et al., 2005) or the transcription factor E2F1 (Hershko and Ginsberg, 2004) .
To examine whether the mitochondrial pathway is required for the synergistic interaction of Doxorubicin and PI3K inhibitors, we overexpressed Bcl-2. Ectopic expression of Bcl-2 almost completely blocked apoptosis upon combined treatment with Doxorubicin and PI103 or LY294002 and inhibited loss of mitochondrial membrane potential, cytochrome c release, cleavage of caspase-9, -3, -8 and Bid, as well as translocation of tBid to the mitochondria (Figures 3a-c) . Interestingly, Bcl-2 overexpression also prevented Bax conformational change ( Figure 3a , right panel), in line with a recently proposed model that Bax activation is modulated by interactions with and within the mitochondrial outer membrane (Yethon et al., 2003; Leber et al., 2007) .
To further delineate the interplay between caspase activation and mitochondrial perturbations, we used the caspase inhibitor zVAD.fmk. Interestingly, zVAD.fmk did not prevent Bax activation (Figure 3d Targeting PI3K in neuroblastoma A Bender et al model, an established in vivo tumor model, for example, also for neuroblastoma (Stupack et al., 2006; Vogler et al., 2008 Vogler et al., , 2009 Hacker et al., 2009) . Intriguingly, PI103 and Doxorubicin cooperated to reduce tumor growth of neuroblastoma in vivo (Figure 4c ). These data in patients' derived primary cultured neuroblastoma cells and in an in vivo model underscore the clinical relevance of our finding that PI3K inhibitors enhance the chemosensitivity of neuroblastoma.
In this study, we show for the first time that the PI3K inhibitor PI103 efficiently sensitizes neuroblastoma cells for chemotherapy-induced apoptosis by shifting the balance towards pro-apoptotic Bcl-2 proteins, thereby enhancing mitochondrial apoptosis (Supplementary Figure 6 ). PI103 cooperates with Doxorubicin to reduce Mcl-1 expression and phosphorylation of Bim EL and to upregulate Noxa and Bim EL levels. This shift in the ratio of pro-and antiapoptotic Bcl-2 proteins initiates Bax/Bak XIAP, Bcl-X L and Bcl-2 was determined by western blotting as described previously (Fulda et al., 1997) . b-Actin served as loading control. (c) SH-EP neuroblastoma cells were treated with 0.6 mM PI103 or 20 mM LY294002 and/or 0.2 mg/ml Doxo for the indicated times. In the left panel, Bax activation was analyzed by immunoprecipitation of protein lysates using the active conformation-specific anti-Bax antibody 6A7 as previously described (Hacker et al., 2009) and Bax expression was analyzed by western blotting. In the right panel, Bak activation was analyzed at 12 h by flow cytometry using an active conformation-specific anti-Bak antibody as previously described (Fakler et al., 2009 Targeting PI3K in neuroblastoma A Bender et al Figure 2 PI3K inhibitors shift the balance towards pro-apoptotic Bcl-2 proteins and cooperate with Doxorubicin to trigger p53-dependent apoptosis. (a, b) SH-EP cells were stably transduced with a vector containing short hairpin RNA (shRNA) against Mcl-1 (a), Noxa (a), p53 (b) or control shRNA using pRETRO-SUPER vector as previously described (Vogler et al., 2007) and shRNA targeting Mcl-1 (Ammann et al., 2009) , Noxa (Alves et al., 2006) , p53 (Brummelkamp et al., 2002) or a sequence with no corresponding part in the human genome (Vogler et al., 2007) . Stable clones were generated by selection with 2 mg/ml puromycin (Clontech, SaintGermain-en Laye, France). Figure 3 Mitochondrial perturbations precede caspase activation upon combined treatment with PI3K inhibitor and Doxorubicin. (a) SH-EP cells were transduced with mouse Bcl-2 (mBcl-2) or pMSCV control vector (EV). Overexpression of mBcl-2 was assessed by western blotting (insert). Transduced cells were treated for 24 h (left panel) or 12 h (right panel) with 0.6 mM PI103 or 20 mM LY294002 and/or 0.2 mg/ml Doxo. Apoptosis was determined by FACS analysis of DNA fragmentation of propidium iodide-stained nuclei (left panel). Bax activation was analyzed by immunoprecipitation of protein lysates using the active conformation-specific anti-Bax antibody 6A7 and Bax expression was analyzed by western blotting (right panel). (b, c) Cells were treated for 12 h with 0.6 mM PI103 or 20 mM LY294002 and/or 0.2 mg/ml Doxo. Mitochondrial transmembrane potential was assessed by flow cytometry using the fluorescent dye CMXRos (b, left panel). Cytochrome c release from mitochondria into the cytosol and translocation of tBid to mitochondria were assessed by western blot analysis (b, right panel). Cytochrome oxidase (COX IV) and a-tubulin were used to control the purity of mitochondrial and cytosolic fractions; tBid is indicated by the arrow. Protein expression of caspase-8, -9, -3, Bid and GAPDH was assessed by western blotting (c). (Kuo et al., 2001) , as well as increased degradation of Mcl-1 via GSK3b or via Noxa (Willis et al., 2005; Maurer et al., 2006; Warr and Shore, 2008) . PI103 may increase Bim EL and Noxa levels via FKHRL1, which is negatively regulated by Akt (Dijkers et al., 2000) and transcriptionally stimulates Bim and Noxa (Dijkers et al., 2000; Obexer et al., 2007) , and/or by preventing the Akt-dependent phosphorylation of Bim EL , which enhances its proteasomal degradation (Qi et al., 2006) . As activation of Bax and Bak occurs before their upregula- (Vogler et al., 2008) , allowed for 48 h to form tumors and treated with 1 mM PI103 and/or 0.0125 mg/ml Doxorubicin for 2 consecutive days. Tumor growth was analyzed using hematoxylin/eosin-stained paraffin sections of the CAM as described previously (Hacker et al., 2009) 
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A Bender et al tion, Doxorubicin-induced accumulation of p53 may directly activate Bax and Bak in a transcription-independent manner (Chipuk et al., 2004; Leu et al., 2004) , whereas PI103 may trigger Bax activation by preventing the Akt-mediated inhibitory phosphorylation of Bax (Yamaguchi and Wang, 2001; Gardai et al., 2004) . There are so far only few studies using PI3K inhibitors as chemosensitizers, for example in T-cell acute lymphoblastic leukemia (Chiarini et al., 2009) , glioblastoma (Guillard et al., 2009; Westhoff et al., 2009) or chronic lymphocytic leukemia (Niedermeier et al., 2009) , and little is yet known about the underlying molecular mechanisms of sensitization. Thus, the novelty of our study resides in particular in the elucidation of the molecular events mediating the cooperative cytotoxicity of the recently developed PI3K inhibitor PI103 and anticancer drugs, such as Doxorubicin, by demonstrating that chemosensitization by PI103 critically depends on mitochondrial outer membrane permeabilization as the result of a shift towards pro-apoptotic Bcl-2 proteins.
Our study has several important implications. First and foremost, our findings are relevant for the design of molecular targeted therapies to increase the efficacy of current chemotherapy protocols in neuroblastoma and build on our recent identification of PI3K/Akt as a potential therapeutic target in neuroblastoma (Opel et al., 2007) . Second, from a mechanistic point of view, our data provide novel insights into the signaling pathways, which can be exploited in combination protocols with PI3K inhibitors and anticancer drugs to achieve synergistic antitumor activities. As PI3K inhibitors are considered as promising targeted cancer therapeutics (Liu et al., 2009) , our results are expected to have an important impact on the development of PI3K inhibitor-based combination regimens for chemosensitization of neuroblastoma and other human cancers.
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